Get startedLog in
    Picture of Tiziana Life Sciences logo

    TLSA — Tiziana Life Sciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    All News

    Brief: Tiziana Life Sciences Plans To Submit Ind For Phase 1 Trial Of Intranasal Foralumab In Alzheimer's Disease Patients

    Picture of Tiziana Life Sciences logoTiziana Life Sciences
    12/10/2022 12:06
    Oct 12 (Reuters) - Tiziana Life Sciences Ltd  TLSA.O :
    * TIZIANA LIFE SCIENCES PLANS TO SUBMIT IND FOR PHASE 1
TRIAL OF
INTRANASAL FORALUMAB IN ALZHEIMER'S DISEASE PATIENTS
    * PLANS ON FILING IND FOR ALZHEIMER'S DISEASE BY Q3 OF 2023,
THEN
STARTING ITS PHASE 1 PROGRAM BY END OF 2023

Source text for Eikon:  ID:nGNX2KGkTq 
Further company coverage:  TLSA.O

    Recent news on Tiziana Life Sciences

    See all news